These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 20672051)

  • 1. The S100B/RAGE Axis in Alzheimer's Disease.
    Leclerc E; Sturchler E; Vetter SW
    Cardiovasc Psychiatry Neurol; 2010; 2010():539581. PubMed ID: 20672051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease.
    Leclerc E; Sturchler E; Vetter SW; Heizmann CW
    Rev Neurosci; 2009; 20(2):95-110. PubMed ID: 19774788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.
    Lue LF; Yan SD; Stern DM; Walker DG
    Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):249-66. PubMed ID: 15975028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis.
    Bortolotto V; Grilli M
    CNS Neurol Disord Drug Targets; 2017; 16(10):1066-1079. PubMed ID: 27488419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S100B protects LAN-5 neuroblastoma cells against Abeta amyloid-induced neurotoxicity via RAGE engagement at low doses but increases Abeta amyloid neurotoxicity at high doses.
    Businaro R; Leone S; Fabrizi C; Sorci G; Donato R; Lauro GM; Fumagalli L
    J Neurosci Res; 2006 Apr; 83(5):897-906. PubMed ID: 16477616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease.
    Walker D; Lue LF; Paul G; Patel A; Sabbagh MN
    Expert Opin Investig Drugs; 2015 Mar; 24(3):393-9. PubMed ID: 25586103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aβ-AGE aggravates cognitive deficit in rats via RAGE pathway.
    Chen C; Li XH; Tu Y; Sun HT; Liang HQ; Cheng SX; Zhang S
    Neuroscience; 2014 Jan; 257():1-10. PubMed ID: 24188791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism.
    Lue LF; Walker DG; Brachova L; Beach TG; Rogers J; Schmidt AM; Stern DM; Yan SD
    Exp Neurol; 2001 Sep; 171(1):29-45. PubMed ID: 11520119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell cycle related signaling in Neuro2a cells proceeds via the receptor for advanced glycation end products.
    Schmidt A; Kuhla B; Bigl K; Münch G; Arendt T
    J Neural Transm (Vienna); 2007; 114(11):1413-24. PubMed ID: 17564756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Trp triad within the V-domain of the receptor for advanced glycation end products modulates folding, stability and ligand binding.
    Indurthi VSK; Jensen JL; Leclerc E; Sinha S; Colbert CL; Vetter SW
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31912881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease.
    Prasad K
    Mol Cell Biochem; 2019 Sep; 459(1-2):95-112. PubMed ID: 31079281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives on RAGE signaling and its role in cardiovascular disease.
    Cohen MM
    Am J Med Genet A; 2013 Nov; 161A(11):2750-5. PubMed ID: 24123885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAGE ligand upregulation of VEGF secretion in ARPE-19 cells.
    Ma W; Lee SE; Guo J; Qu W; Hudson BI; Schmidt AM; Barile GR
    Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1355-61. PubMed ID: 17325184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease.
    Chen X; Walker DG; Schmidt AM; Arancio O; Lue LF; Yan SD
    Curr Mol Med; 2007 Dec; 7(8):735-42. PubMed ID: 18331231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains.
    Leclerc E; Fritz G; Weibel M; Heizmann CW; Galichet A
    J Biol Chem; 2007 Oct; 282(43):31317-31. PubMed ID: 17726019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?
    Yan SD; Bierhaus A; Nawroth PP; Stern DM
    J Alzheimers Dis; 2009; 16(4):833-43. PubMed ID: 19387116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor for advanced glycation end products mediates sepsis-triggered amyloid-β accumulation, Tau phosphorylation, and cognitive impairment.
    Gasparotto J; Girardi CS; Somensi N; Ribeiro CT; Moreira JCF; Michels M; Sonai B; Rocha M; Steckert AV; Barichello T; Quevedo J; Dal-Pizzol F; Gelain DP
    J Biol Chem; 2018 Jan; 293(1):226-244. PubMed ID: 29127203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of RAGE in Alzheimer's Disease.
    Cai Z; Liu N; Wang C; Qin B; Zhou Y; Xiao M; Chang L; Yan LJ; Zhao B
    Cell Mol Neurobiol; 2016 May; 36(4):483-95. PubMed ID: 26175217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution and Relative Abundance of S100 Proteins in the Brain of the APP23 Alzheimer's Disease Model Mice.
    Hagmeyer S; Romão MA; Cristóvão JS; Vilella A; Zoli M; Gomes CM; Grabrucker AM
    Front Neurosci; 2019; 13():640. PubMed ID: 31281238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.
    Srikanth V; Maczurek A; Phan T; Steele M; Westcott B; Juskiw D; Münch G
    Neurobiol Aging; 2011 May; 32(5):763-77. PubMed ID: 19464758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.